These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26698850)

  • 1. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
    Dreyer L; Magyari M; Laursen B; Cordtz R; Sellebjerg F; Locht H
    Ann Rheum Dis; 2016 Apr; 75(4):785-6. PubMed ID: 26698850
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
    Sørensen J; Hetland ML;
    Ann Rheum Dis; 2015 Mar; 74(3):e12. PubMed ID: 24534758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.
    Glintborg B; Østergaard M; Dreyer L; Krogh NS; Tarp U; Hansen MS; Rifbjerg-Madsen S; Lorenzen T; Hetland ML
    Arthritis Rheum; 2011 Feb; 63(2):382-90. PubMed ID: 21279995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
    Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
    Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
    Glintborg B; Højgaard P; Lund Hetland M; Steen Krogh N; Kollerup G; Jensen J; Chrysidis S; Jensen Hansen IM; Holland-Fischer M; Højland Hansen T; Nilsson C; Espesen J; Nordin H; Rasmussen Loft AG; Pelck R; Lorenzen T; Flejsborg Oeftiger S; Unger B; Jaeger F; Mosborg Petersen P; Rasmussen C; Dreyer L
    Rheumatology (Oxford); 2016 Apr; 55(4):659-68. PubMed ID: 26628579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer in arthritis patients after anti-tumour necrosis factor therapy].
    Dreyer L; Mellemkjaer L; Hetland ML
    Ugeskr Laeger; 2009 Feb; 171(7):506-11. PubMed ID: 19210932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M; Favalli EG
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
    J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P; Jamieson B; Hoffman R
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract]   [Full Text] [Related]  

  • 18. Comment on 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry'.
    Feldtkeller E; Rudwaleit M
    Ann Rheum Dis; 2014 Dec; 73(12):e77. PubMed ID: 25252720
    [No Abstract]   [Full Text] [Related]  

  • 19. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.